Whether mirikizumab has been included in medical insurance and related policies

Mirikizumab is a humanized monoclonal antibody targeting the IL-23 pathway and is mainly used to treat moderately to severely active ulcerative colitis and Crohn's disease. The drug was developed by Lilly (Lilly) and has been approved for marketing in many European and American countries, and has become one of the important treatment options in the field of IL-23 target. However, as of now, Militizumab has not been approved for marketing in mainland China, nor has it been included in the national medical insurance directory. Domestic patients who need medication can only obtain it through overseas channels.

In terms of medical insurance, Militizumab has not yet been included in China's medical insurance reimbursement catalog. Therefore, regardless of whether it is purchased through overseas agents or goes abroad for medical treatment, patients cannot obtain medical insurance support and must bear all costs at their own expense. Since it has not yet completed domestic registration approval and is not within the scope of national medical insurance negotiations, the possibility of being included in medical insurance in the short term is low. Patients are advised to pay attention to follow-up policies and marketing trends and keep abreast of progress information.

According to public information from overseas markets, the original drug of militizumab has been launched in Europe and other regions. The common specification is 300mg/15ml a box, priced at about more than 10,000 yuan. Because the drug is a biological agent, its manufacturing cost is high, resulting in a price much higher than that of traditional chemical drugs. Although insurance coverage or medical assistance programs are available in some areas, the financial pressure for Chinese patients to purchase drugs overseas is still relatively high.

In general, militizumab is not currently on the market in China, nor is it included in medical insurance reimbursement. Domestic patients cannot obtain it through formal channels for the time being. Although overseas original drugs have been put into use in many countries, high drug prices and difficulty in importing limit the accessibility to domestic patients. It is recommended that patients in need of treatment weigh the pros and cons under the guidance of professional doctors, carefully consider whether to obtain it through cross-border channels based on their condition and financial ability, and pay attention to the future domestic launch of drugs and medical insurance negotiations.

Reference materials:https://www.drugs.com/